Lv1
40 积分 2026-07-08 加入
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study
14小时前
待确认
Precision medicine in Sjögren's disease
17小时前
已完结
The STING/type I interferon axis drives the interplay between marginal zone B cells and T follicular helper cells in Sjögren’s disease
1天前
已完结
皖公网安备34019202002308
